Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Foghorn Therapeutics Inc. (FHTX) Market Cap & Valuation Ratios

Foghorn Therapeutics Inc. (FHTX) has a market cap of $118.8M and a price-to-sales ratio of 3.2, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

FHTXFoghorn Therapeutics Inc.Follow FHTX — free
Drug Manufacturers - General · Healthcare
—
Price chart with a free account
Market cap
118.8M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
10 Nov, in 17 days

Peers

drug manufacturers - general · nearest by market cap · trailing 12 months
CompanyMkt cap, $BP/EEV/SalesEV/EBITDAFCF yieldRev. growthOp. marginROIC
FHTX0.1—1.4——+52%-198%—
TTRX0.3———-1.4%———
BNTC0.3———-5.5%———
PRLD0.3—6.2—-11.5%+220%-301%-86%
IRD0.3—24.0—-12.2%-36%——
QNRX0.3———-5.4%———
AMRN0.3———6.0%-15%-22%-13%
ABEO0.3—4.7———-328%-157%
LYEL0.2—963.0——-55%—-142%
EVMN0.2————+86%—-47%
YARW0.1—59.2——+1%——
Median of these 10—24.0—-5.5%-7%-301%-86%

; EV/Sales 1.4 vs. 24.0.

Growth vs. price

each dot a company · hover or tap for values

Foghorn Therapeutics Inc. — questions

What is Foghorn Therapeutics Inc.'s market cap?
$118.8M.
What is Foghorn Therapeutics Inc.'s price-to-sales ratio?
3.2.

Every figure on this page comes from Foghorn Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.